Spotlight on afatinib and its potential in the treatment of squamous cell lung cancer: the evidence so far

Compared to adenocarcinoma, fewer effective treatment options are available for advanced or metastatic squamous cell carcinoma (SCC) of the lung. Afatinib is an orally administered, irreversible EGFR antagonist. As a second-generation tyrosine kinase inhibitor, it has been applied in the treatment o...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Yijun, Ding, Vivianne W, Zhang, Hong, Zhang, Xun, Jablons, David, He, Biao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4888861/
https://www.ncbi.nlm.nih.gov/pubmed/27307741
http://dx.doi.org/10.2147/TCRM.S92996

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4888861/
https://www.ncbi.nlm.nih.gov/pubmed/27307741
http://dx.doi.org/10.2147/TCRM.S92996

Ejemplares similares